We did not identify established human drug-exposure studies for PEG-MGF. The available evidence is mainly laboratory work on related growth-factor biology, with conflicting findings, so human muscle or recovery claims are not established.
Still uncertain: Whether it improves muscle or recovery in people, how the body handles it, optimal research exposure, long-term safety or equivalence of commercial PEG-MGF to laboratory MGF peptides.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
FDA reports no identified human exposure data for PEG-MGF drug products. Published human-cell studies concern MGF peptides rather than a validated PEG-MGF clinical product.
Regulatory status
Not FDA-approved; FDA highlights absence of human exposure and safety data for PEG-MGF.
Main limitations
Human muscle-building/recovery efficacy, pharmacokinetics, optimal exposure, long-term safety or equivalence of commercial PEG-MGF to laboratory MGF peptides.
Safety
Unknown human safety; potential growth-factor and immunogenicity concerns.
Evidence reviewed
2026-09-18
i
FDA reports no identified human exposure data for PEG-MGF drug products. Published human-cell studies concern MGF peptides rather than a validated PEG-MGF clinical product.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Unknown human safety; potential growth-factor and immunogenicity concerns.
Human safety is unknown; growth-factor pathway, PEGylation, immunogenicity, peptide impurities and uncertain product identity are relevant risks.
Technical details
Mechanism / biologyIntended to mimic/extend activity attributed to mechano-growth-factor peptide sequences; product definitions vary.
Route / formulation boundaryDo not confuse PEG-MGF with PEG-rHuMGDF (pegylated thrombopoietic growth factor), a different molecule in older literature.
Study / label regimen evidenceStudy-regimen evidence reviewed. No verified human drug-exposure regimen identified; preclinical/community protocols should not be presented as human dosing evidence.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
1outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
